Coagulation Factor Concentrates Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type (Hemophilia A, Hemophilia B, Van Willebrand Disease, Others), By Application (Immunology, Neurology, Hematology, Critical Care, Others), By End Users (Hospitals & Clinics, Clinical Research Laboratories, Others), and Region Forecast 2020-2031

Coagulation Factor Concentrates Market size was valued at US$ 6.2 billion in 2024 and is expected to reach US$ 11.4 billion by 2031, growing at a significant CAGR of 6.1% from 2025-2031. Moreover, the U.S. Coagulation Factor Concentrates Market is projected to grow significantly, reaching an estimated value of US$ 2.4 Billion by 2031. The market relies on the production and supply of therapy for the cure of bleeding disorders caused by deficiency or abnormality of coagulation protein. The therapy, ranging from plasma-derived to recombinant factor concentrates, plays an important role in maintaining normal blood clotting in hemophilia A and B, von Willebrand disease, and other rare coagulopathies. With effective control, they allow patients to reduce the frequency of bleeding episodes and enhance the overall quality of life.

The industry keeps on increasing with improvements in biotechnology like improvement in recombinant DNA technology and gene therapy, which ensure longer and safer duration of treatment. Increased rates of diagnosis, improved recognition of bleeding disorders, and increased access to medical therapy in the developing world also accelerate the growth. In addition, improved investigation into new therapies and personalized medicine further increase the efficacy and convenience of treatment, driving the move towards more convenient and advanced care.

Facts & Figures

• According to recent statistics, hemophilia affects an estimated 400,000 people worldwide, with only about 25% receiving adequate treatment.
• High prevalence rate underscores the demand for effective therapies and highlights the market potential for coagulation factor concentrates. As awareness and diagnostic capabilities improve globally, the demand for these concentrates is anticipated to grow further, driving market expansion.
• As of June 2024, the WHO reports that injuries from accidents and violence result in 4.4 million deaths worldwide annually, making up nearly 8% of all deaths. For those aged 5-29, road accidents, homicide, and suicide are three leading causes of death.

Key Developments:

• In March 2025, The U.S. Food and Drug Administration has approved Qfitlia (fitusiran) as a routine prophylactic treatment for individuals aged 12 and older with hemophilia A or B, including those who have factor VIII or IX inhibitors. This milestone broadens available treatment options, offering effective bleeding episode reduction for a wider range of patients.
• In Dec 2024, India’s first gene therapy for Severe Hemophilia A showed sustained Factor VIII production and zero bleeding episodes in a single-center study. This breakthrough offers new hope for affordable, long-term treatments in the coagulant factor market, especially in low-resource settings.
• In October 2024, The U.S. Food and Drug Administration has granted approval for Hympavzi (marstacimab-hncq) as a routine prophylactic treatment aimed at preventing or reducing bleeding episodes. This therapy is designated for adults and children aged 12 and older who have hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies), providing an important advancement in managing these conditions.
• In November 2023, Ethicon, a Johnson & Johnson MedTech company, received approval for ETHIZIA, a hemostat solution proven to effectively control challenging bleeding. The ETHIZIA Hemostatic Sealing Patch, the first of its kind, features unique synthetic polymer technology that works equally well on both sides.

Coagulation Factor Concentrates Market Segmentation:

Based on the type:

• Hemophilia A
• Hemophilia B
• Van Willebrand Disease
• Others

Hemophilia A segment of the coagulation factor market has the largest market share because of its increased prevalence and continuous innovation in factor VIII concentrates. Technological advances like extended half-life and recombinant factor VIII solutions have improved treatment effectiveness and patient convenience, promoting usage. Hemophilia A is also supported by massive patient advocate group support and extensive clinical trials, driving access and awareness. In contrast, Hemophilia B, though as important, appears to have a comparatively smaller patient population and fewer candidates in development. Emphasis on gene and customized treatments for Hemophilia A further strengthens it as the market leader.

Based on the application, the Market is segmented into the following

• Immunology
• Neurology
• Hematology
• Critical care
• Others

The hematology sector hold the largest share in the market for coagulation factors because of its primacy in treating bleeding disorders such as hemophilia A and B. Coagulation factors are essential for replacing missing or deficient clotting proteins to achieve ideal bleeding control and complication avoidance. Advances in scientific technologies such as recombinant and long-acting half-life preparations have maximized the efficacy of treatment, compliance, and quality of life. Increased detection and expanded diagnostic coverage have accelerated early intervention rates, further driving demand in hematology. Supportive government policies and increasing availability in developing markets are accelerating adoption, with hematology becoming the top application to drive market growth.

Based on the End User:

• Hospitals & Clinics
• Clinical Research Laboratories
• Others

Hospitals and clinics are the most invested in the coagulation factor concentrate market because of their role at the core of overall hemophilia and bleeding disorders management. These centers have controlled environments for safe storage, handling, and distribution of sophisticated coagulation therapies such as recombinant and extended half-life products that need special monitoring. Their ability for acute and prophylactic interventions coupled with multidisciplinary care teams guarantees maximized patient outcomes. In addition, hospitals and clinics enable various patient assessment and treatment individualization necessary for the treatment of complicated bleeding profiles. Greater inclusion of digital health tools within these facilities further contributes to the accuracy of treatment, solidifying their role as key players as lead end users in this space.